FL-SINTAVIA
10.4.2024 14:00:28 CEST | Business Wire | Press release
Sintavia, LLC, the world’s first all-digital aerospace component manufacturer, today announced its single largest expansion in facilities and equipment since 2019. The $25 million investment includes additional advanced manufacturing space, large format printers, large format post-processing equipment, and component testing equipment. It is expected that with this investment, Sintavia will be able to meet the demand from the programs it supports across the U.S. Department of Defense for the balance of this decade.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240405121388/en/
As part of its announced expansion, Sintavia purchased a second SLM NXG XII 600 printer (Photo: Business Wire)
“Looking into the next few years, it is clear to us that we need to make the investments today that will support the demand from our customers tomorrow,” said Brian Neff, Sintavia’s Founder and CEO. “As the world’s first truly all-digital aerospace component supplier, Sintavia is in a unique position to push the boundaries of what is possible in terms of designing and manufacturing next generation aerospace components along a single, fully digital thread. But to do that, you need first to have the right facilities, hardware, and software in place. That is what we are doing today in support of our customers and their critical programs.”
A major focus of the new expansion will be the continued design and development of high-performance thermodynamic components, in particular aerospace heat exchangers. Sintavia’s heat exchangers, which are enabled using additively designed triply periodic minimal surface structures, demonstrate improved heat rejection at comparative flow rates when evaluated against traditional versions. Additionally, the manufacturing sturdiness of a fully digital thread results in production yields close to 100%, multiples higher than manufacturing yields often experienced by traditional heat exchanger manufacturers.
As part of the expansion, Sintavia signed a long-term lease on an additional 25,000 ft2 of manufacturing space adjacent to its existing headquarters, which it will use for printing, post-processing, and materials testing. New equipment included in the expansion includes Sintavia’s second SLM NXG XII 600, a third AMCM M4K-4, a second CT Scanner (450 kV), a second large air furnace, cold flow test machine, a shock and vibration table, pressure cycle testing equipment, acoustic testing equipment, multiple additional 5-axis CNC machines, multiple additional fatigue rigs, and multiple additional polishing machines. As it announced last October, Sintavia is also the North American launch customer for the AMCM M8K-K, the world’s largest industrially viable laser powder bed fusion printer, with an impressive cubic displacement of 38 ft3.
The expansion is expected to be completed by the fourth quarter of 2024.
About Sintavia
Sintavia is the world's first all-digital Aerospace & Defense component manufacturer. A founding member of the Additive Manufacturer Green Trade Association, Sintavia is committed to the highest quality standards in the industry and holds multiple Nadcap and other aerospace accreditations. For more information visit http://www.sintavia.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240405121388/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
Speech Processing Solutions Launches Philips SpeechLive Legal AI Assistant for Faster, More Accurate Legal Document Creation5.8.2026 15:37:00 CEST | Press release
The new SpeechLive Legal AI Assistant reduces the administrative burden on legal professionals through customizable document drafting powered by speech recognition tuned for legal terminology Speech Processing Solutions, the global leader in AI-assisted professional dictation and documentation solutions sold under the Philips brand, today announced the Philips SpeechLive Legal AI Assistant. The new solution transforms voice recordings, dictation and uploaded sources into structured, ready-to-review legal documents, helping legal professionals work faster while retaining control of the final draft. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805997413/en/ The new Philips SpeechLive Legal AI Assistant is designed for turning conversations into ready-to-review legal document drafts. SpeechLive Legal significantly reduces the time needed to transform voice input into structured legal documentation, delivering consistent an
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
